Data: your company’s hidden asset
How to identify, protect and exploit the data you already have
Read moreToday's top story
Out-Law Analysis
Cell and gene therapies: resilience the aim in 2023 amidst regulatory flux
Diversification, collaboration and consolidation are likely to be emerging themes in the cell and gene therapies (CGTs) market globally in 2023 and beyond, as developers seek to make their businesses resilient to the economic headwinds they face.
Life Sciences & HealthFeatured Thinking
Latest press releases
Show me all press releasesPinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan
Pinsent Masons advises PIC on £132m buy-in of Tomkins 2008 pension scheme retirement benefits plan.
Pinsent Masons advises on Umicore’s € 591 million sustainability linked note fundraising
Multinational law firm Pinsent Masons has advised various institutional investors in relation to Umicore’s € 591 million sustainability linked note fundraising.
Pinsent Masons advises Alveo on its sale to Symphony Technology Group
Pinsent Masons has advised the shareholders of Alveo, including funds managed by Sovereign Capital Partners (SCP), on its sale to Symphony Technology Group (STG).
Winner
Legal Business
Law Firm of the Year 2021
Winner
Financial Times
Most Innovative Law Firm - Europe 2020
